Evans John's most recent trade in Beam Therapeutics Inc was a trade of 180,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 29, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2026 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 25,000 | 68,672 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.67 per share. | 29 Jan 2026 | 25,000 | 1,011,667 (2%) | 0% | 0.7 | 16,750 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 28.27 per share. | 29 Jan 2026 | 22,094 | 989,573 (1%) | 0% | 28.3 | 624,672 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 19,336 | 0 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.67 per share. | 29 Jan 2026 | 19,336 | 1,006,003 (2%) | 0% | 0.7 | 12,955 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 29.19 per share. | 29 Jan 2026 | 16,333 | 995,334 (2%) | 0% | 29.2 | 476,801 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 29.74 per share. | 29 Jan 2026 | 8,667 | 986,667 (1%) | 0% | 29.7 | 257,781 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.67 per share. | 29 Jan 2026 | 5,664 | 1,011,667 (2%) | 0% | 0.7 | 3,795 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 5,664 | 93,672 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 29.00 per share. | 29 Jan 2026 | 2,906 | 986,667 (1%) | 0% | 29 | 84,274 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 24.51 per share. | 01 Oct 2025 | 25,000 | 986,667 (1%) | 0% | 24.5 | 612,655 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.67 per share. | 01 Oct 2025 | 25,000 | 1,011,667 (2%) | 0% | 0.7 | 16,750 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.67 per share. | 01 Oct 2025 | 25,000 | 1,011,667 (2%) | 0% | 0.7 | 16,750 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2025 | 25,000 | 19,336 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2025 | 25,000 | 44,336 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 24.63 per share. | 01 Oct 2025 | 25,000 | 986,667 (1%) | 0% | 24.6 | 615,668 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 18.35 per share. | 01 Apr 2025 | 30,663 | 986,249 (1%) | 0% | 18.4 | 562,684 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 77,500 | 1,016,159 (2%) | 0% | 0 | Common Stock | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 155,000 | 155,000 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 30,000 | 69,336 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.67 per share. | 30 Jan 2025 | 30,000 | 968,659 (1%) | 0% | 0.7 | 20,100 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 26.75 per share. | 30 Jan 2025 | 29,800 | 908,859 (1%) | 0% | 26.7 | 797,028 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 27.28 per share. | 30 Jan 2025 | 200 | 908,659 (1%) | 0% | 27.3 | 5,456 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 24.60 per share. | 30 Sep 2024 | 60,000 | 938,659 (1%) | 0% | 24.6 | 1,476,024 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 24.50 per share. | 27 Jun 2024 | 60,000 | 998,343 (2%) | 0% | 24.5 | 1,470,156 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 99,336 | 99,336 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 53,965 | 53,965 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 32.13 per share. | 01 Apr 2024 | 18,102 | 1,058,343 (2%) | 0% | 32.1 | 581,617 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2024 | 77,500 | 1,076,445 (2%) | 0% | 0 | Common Stock | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 33.86 per share. | 28 Mar 2024 | 60,000 | 998,262 (2%) | 0% | 33.9 | 2,031,402 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 155,000 | 155,000 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | Evans John | Director, CEO | Sale of securities on an exchange or to another person at price $ 25.33 per share. | 31 Jan 2024 | 60,000 | 1,058,262 (2%) | 0% | 25.3 | 1,519,800 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 29.09 per share. | 03 Apr 2023 | 6,493 | 1,117,979 (2%) | 0% | 29.1 | 188,904 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 30.31 per share. | 03 Apr 2023 | 5,161 | 1,124,472 (2%) | 0% | 30.3 | 156,430 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 112,500 | 112,500 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 56,250 | 1,115,303 (2%) | 0% | 0 | Common Stock | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.22 per share. | 31 Jan 2023 | 13,850 | 1,129,153 (2%) | 0% | 7.2 | 99,997 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 13,850 | 196,904 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | 31 Jan 2023 | 225 | 1,059,053 (2%) | 0% | 0 | Common Stock | ||
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 46.88 per share. | 31 Oct 2022 | 11,756 | 1,061,429 (2%) | 0% | 46.9 | 551,137 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 46.91 per share. | 31 Oct 2022 | 8,235 | 105,188 (0%) | 0% | 46.9 | 386,339 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 46.19 per share. | 31 Oct 2022 | 7,768 | 1,073,185 (2%) | 0% | 46.2 | 358,819 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 44.92 per share. | 31 Oct 2022 | 7,567 | 1,080,953 (2%) | 0% | 44.9 | 339,944 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 44.93 per share. | 31 Oct 2022 | 5,008 | 117,992 (0%) | 0% | 44.9 | 224,993 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 46.19 per share. | 31 Oct 2022 | 4,569 | 113,423 (0%) | 0% | 46.2 | 211,034 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 47.89 per share. | 31 Oct 2022 | 2,909 | 1,058,520 (2%) | 0% | 47.9 | 139,325 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 47.91 per share. | 31 Oct 2022 | 2,188 | 103,000 (0%) | 0% | 47.9 | 104,836 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 65.82 per share. | 28 Jul 2022 | 15,236 | 1,093,103 (2%) | 0% | 65.8 | 1,002,896 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 65.92 per share. | 28 Jul 2022 | 10,599 | 125,448 (0%) | 0% | 65.9 | 698,673 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 64.87 per share. | 28 Jul 2022 | 10,181 | 1,108,339 (2%) | 0% | 64.9 | 660,429 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 64.88 per share. | 28 Jul 2022 | 6,953 | 136,047 (0%) | 0% | 64.9 | 451,113 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 67.80 per share. | 28 Jul 2022 | 2,848 | 1,088,693 (2%) | 0% | 67.8 | 193,093 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 67.82 per share. | 28 Jul 2022 | 2,247 | 123,000 (0%) | 0% | 67.8 | 152,383 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 66.74 per share. | 28 Jul 2022 | 1,562 | 1,091,541 (2%) | 0% | 66.7 | 104,255 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 66.61 per share. | 28 Jul 2022 | 201 | 125,247 (0%) | 0% | 66.6 | 13,389 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 68.49 per share. | 28 Jul 2022 | 173 | 1,088,520 (2%) | 0% | 68.5 | 11,849 | Common Stock |
| Verve Therapeutics Inc | John Evans | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 15,500 | 15,500 | - | - | Stock Option (right to buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.03 per share. | 28 Apr 2022 | 47,204 | 1,148,520 (2%) | 0% | 1.0 | 48,620 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 47,204 | 237,141 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 37.48 per share. | 28 Apr 2022 | 13,655 | 1,130,965 (2%) | 0% | 37.5 | 511,789 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.22 per share. | 28 Apr 2022 | 12,246 | 1,101,316 (2%) | 0% | 7.2 | 88,416 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 12,246 | 210,754 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 37.84 per share. | 28 Apr 2022 | 7,745 | 148,805 (0%) | 0% | 37.8 | 293,071 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 38.32 per share. | 28 Apr 2022 | 6,842 | 1,124,123 (2%) | 0% | 38.3 | 262,185 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 36.98 per share. | 28 Apr 2022 | 6,450 | 156,550 (0%) | 0% | 37.0 | 238,521 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 39.49 per share. | 28 Apr 2022 | 4,503 | 1,119,620 (2%) | 0% | 39.5 | 177,823 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 36.59 per share. | 28 Apr 2022 | 3,900 | 1,144,620 (2%) | 0% | 36.6 | 142,701 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 38.75 per share. | 28 Apr 2022 | 3,100 | 145,705 (0%) | 0% | 38.8 | 120,125 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 39.73 per share. | 28 Apr 2022 | 2,348 | 143,357 (0%) | 0% | 39.7 | 93,286 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 40.73 per share. | 28 Apr 2022 | 1,100 | 1,118,520 (2%) | 0% | 40.7 | 44,803 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 40.88 per share. | 28 Apr 2022 | 357 | 143,000 (0%) | 0% | 40.9 | 14,594 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 56,250 | 1,095,331 (2%) | 0% | 0 | Common Stock | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 59.11 per share. | 31 Mar 2022 | 6,261 | 1,089,070 (2%) | 0% | 59.1 | 370,088 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 112,500 | 112,500 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 100,000 | 284,345 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.03 per share. | 31 Jan 2022 | 100,000 | 1,038,825 (2%) | 0% | 1.0 | 103,000 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 67.44 per share. | 31 Jan 2022 | 13,535 | 942,803 (1%) | 0% | 67.4 | 912,800 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Jan 2022 | 12,000 | 968,825 (1%) | 0% | 0 | Common Stock | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 67.43 per share. | 31 Jan 2022 | 9,408 | 165,672 (0%) | 0% | 67.4 | 634,381 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 66.55 per share. | 31 Jan 2022 | 6,337 | 956,338 (1%) | 0% | 66.5 | 421,727 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 66.48 per share. | 31 Jan 2022 | 4,105 | 175,080 (0%) | 0% | 66.5 | 272,900 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 68.15 per share. | 31 Jan 2022 | 3,978 | 938,825 (1%) | 0% | 68.2 | 271,101 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 65.49 per share. | 31 Jan 2022 | 3,177 | 962,675 (1%) | 0% | 65.5 | 208,062 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 68.16 per share. | 31 Jan 2022 | 2,672 | 163,000 (0%) | 0% | 68.2 | 182,124 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 64.47 per share. | 31 Jan 2022 | 2,172 | 965,852 (1%) | 0% | 64.5 | 140,029 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 65.55 per share. | 31 Jan 2022 | 1,900 | 179,185 (0%) | 0% | 65.6 | 124,545 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 64.46 per share. | 31 Jan 2022 | 1,615 | 181,085 (0%) | 0% | 64.5 | 104,103 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 63.79 per share. | 31 Jan 2022 | 801 | 968,024 (1%) | 0% | 63.8 | 51,096 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 63.45 per share. | 31 Jan 2022 | 300 | 182,700 (0%) | 0% | 63.5 | 19,035 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2021 | 27,700 | 331,645 | - | - | Stock Option (Right to Buy) | |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.03 per share. | 06 Oct 2021 | 27,700 | 1,061,225 (2%) | 0% | 1.0 | 28,531 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 83.47 per share. | 06 Oct 2021 | 13,406 | 1,044,670 (2%) | 0% | 83.5 | 1,118,999 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 84.45 per share. | 06 Oct 2021 | 10,444 | 1,034,226 (2%) | 0% | 84.5 | 881,996 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 83.49 per share. | 06 Oct 2021 | 9,863 | 190,966 (0%) | 0% | 83.5 | 823,462 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 84.45 per share. | 06 Oct 2021 | 7,566 | 183,400 (0%) | 0% | 84.5 | 638,949 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 82.72 per share. | 06 Oct 2021 | 3,149 | 1,058,076 (2%) | 0% | 82.7 | 260,485 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 82.71 per share. | 06 Oct 2021 | 2,171 | 200,829 (0%) | 0% | 82.7 | 179,563 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 85.19 per share. | 06 Oct 2021 | 701 | 1,033,525 (2%) | 0% | 85.2 | 59,718 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Sale of securities on an exchange or to another person at price $ 85.24 per share. | 06 Oct 2021 | 400 | 183,000 (0%) | 0% | 85.2 | 34,096 | Common Stock |
| Beam Therapeutics Inc | John Evans | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2021 | 12,000 | 359,345 | - | - | Stock Option (Right to Buy) |